Loading...
Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research
Rilotumumab is a fully human monoclonal antibody against hepatocyte growth factor, the only known ligand of the MET receptor. Over the last decade, rilotumumab has been extensively tested in preclinical studies and in clinical studies in a variety of cancer types. In this review, we examine the phar...
Na minha lista:
| Udgivet i: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley & Sons, Ltd
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4631169/ https://ncbi.nlm.nih.gov/pubmed/25912961 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12663 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|